NeuroAct Communication offers expert guidance to scientific communication.

  • Define a publication strategy: identify objectives, target audience, journals
  • Aid to effective presentation of pharmacological data
  • Experienced scientific writing and editing: research reports, posters, symposia

For more information Contact.
 

 

Pharmacology of “atypicality” of antipsychotic drugs: status and perspectives. (REVIEW) PDF

Newman-Tancredi A., Kleven M.S.
Archives of Psychiatry & Psychotherapy. 2010; 4:5-11.

Free Full-Text

 

"Atypical" antipsychotics are antagonists at serotonin 5-HT2A and dopamine D2 receptors. However, their effects on negative symptoms and cognitive deficits remain modest and they disrupt metabolic function. Recent drugs such as aripiprazole, perospirone, bifeprunox, lurasidone and cariprazine act as D2 receptor antagonists (or partial agonists) combined with 5-HT1A receptor activation. The latter prevents extrapyramidal symptoms, favors prefrontal cortex neurotransmission, has beneficial influence on mood and opposes cognitive deicits. Further, recent drugs exhibit little interation with sites associated with side-effects such as metabolic disorders or autonomic disturbance. However, these drugs differ in their balance of 5-HT1A/D2 receptor properties and this is likely to translate to distinct therapeutic profiles.